American Capital Management Inc. Decreases Stock Holdings in NeoGenomics, Inc. $NEO

American Capital Management Inc. lowered its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,250,878 shares of the medical research company’s stock after selling 73,488 shares during the period. American Capital Management Inc. owned 1.73% of NeoGenomics worth $16,702,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Aberdeen Group plc lifted its holdings in NeoGenomics by 127.1% during the 4th quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock worth $21,156,000 after buying an additional 1,006,676 shares during the last quarter. Granite Investment Partners LLC purchased a new position in shares of NeoGenomics in the 1st quarter valued at about $5,583,000. First Trust Advisors LP purchased a new position in shares of NeoGenomics in the 1st quarter valued at about $45,725,000. Louisiana State Employees Retirement System acquired a new stake in shares of NeoGenomics during the 1st quarter worth about $426,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of NeoGenomics during the 1st quarter worth about $562,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

NEO has been the subject of several recent analyst reports. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $12.00 to $25.00 in a research note on Wednesday, April 29th. TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Benchmark boosted their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.57.

NeoGenomics Trading Down 5.4%

NASDAQ:NEO opened at $13.14 on Tuesday. The stock’s 50 day moving average price is $12.29 and its 200 day moving average price is $10.65. The company has a market capitalization of $1.71 billion, a PE ratio of -17.06 and a beta of 1.74. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41. NeoGenomics, Inc. has a 52-week low of $4.72 and a 52-week high of $15.57.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $186.67 million during the quarter, compared to analysts’ expectations of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The company’s quarterly revenue was up 11.3% on a year-over-year basis. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.15 EPS for the current year.

Insider Activity at NeoGenomics

In other news, Director Lynn A. Tetrault sold 5,307 shares of NeoGenomics stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total value of $59,916.03. Following the transaction, the director directly owned 91,422 shares of the company’s stock, valued at $1,032,154.38. The trade was a 5.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is owned by insiders.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.